BioSpace News Archive

MilliporeSigma, a leading provider of functional genomics screening and genome- editing tools, has launched its CRISPR inhibition (CRISPRi) whole-genome libraries and pools to complement its industry-leading suite of genome-editing products and technologies.

Xeris Pharmaceuticals, Inc. announced that on March 31, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 15,250 shares of its common stock to 10 new employee under Xeris’ Inducement Equity Plan.

PRINCETON, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the appointment of Shaundra Clay to its board of directors, effective today. “We are delighted to welcome Shaundra, a seasoned senior executive with a proven record of achievement in finance and strategy across diverse industries,” said Stuart Essig, chairman of the Integra board of directors. “Her extensive experience and

Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 83,599 shares of common stock with a grant date of March 31, 2021 for two new employees.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter of Fiscal 2021 on Wednesday, May 5, 2021, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 5, 2021.

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus ® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

CytRx Corporation (OTCQB: CYTR) (“CytRx”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) announced that its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis (“IBM”) did not meet its primary and secondary endpoints.

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees.

IVERIC bio, Inc. reported that on April 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.

StageZero Life Sciences, Ltd. ( reports financial results for the three and twelve months ended December 31, 2020, and provides an update on its business progress.